Why the study?
Do heart rate-lowering calcium antagonists reduce mortality and event rates in hypertensive post-myocardial infarction patients?
Do heart rate-lowering calcium antagonists reduce mortality and event rates in hypertensive post-myocardial infarction patients?
Heart rate-lowering calcium antagonists decrease event rates in hypertensive post-myocardial infarction patients, but this benefit is restricted to those without pulmonary congestion.
Answers are grounded in this paper and cite their sources.
Reduces event rates without lowering mortality in hypertensive post-MI patients; extends evidence for heart rate-lowering calcium antagonists in this setting.
OBJECTIVES: To analyse effects of a heart rate-lowering calcium antagonist in hypertensive post-myocardial infarction patients. DESIGN AND METHODS: From three large, randomized, placebo-controlled, secondary prevention trials investigating verapamil or diltiazem (the first and second Danish Verapamil Infarction Trials and the Multicentre Diltiazem Post-Infarction Trial) data from a total of 1,325 hypertensive post-myocardial infarction patients (drugs = 667, placebo = 658) were pooled to assess effect of blinded therapy on mortality and event rates. RESULTS: Treatment with heart rate-lowering calcium antagonists was associated with significant reduction in event rates [21.4 versus 27.4%; risk ratio (RR) = 0.76, confidence interval (CI) = 0.61 -0.95, P= 0.013]. Mortality rates in the treatment group were 15.1 versus 17.5% in the control group (RR = 0.87, CI = 0.66-1.13, P= 0.296). Among the subset of 964 hypertensive patients without pulmonary congestion, there was some reduction in mortality rate (11.3 versus 15.3% in the control group; RR = 0.72, P= 0.066) and significant reduction in event rates (18 versus 24.4% for control group; RR = 0.70, P= 0.011). In patients with pulmonary congestion and hypertension, however, calcium antagonists were associated with a 25% increase in mortality (RR = 1.25, P= 0.339), while event rate RR was 1.00. After an adjustment for significant covariates, RR for mortality in treatment versus control groups was 0.76 (P= 0.159). For event rates, RR was 0.74 (P= 0.057). CONCLUSIONS: Heart rate-lowering calcium antagonists decrease event rates in hypertensive post-myocardial infarction patients, but only in those without pulmonary congestion.
No takes yet. Share an insight, caveat, or question.
Messerli et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: